ArticleInternational journal of women's health2026
Rheumatic Heart Disease Burden and Sex Differences in China and ASEAN Countries, 1990-2030: A Comparative Analysis from the Global Burden of Disease Study 2023.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rheumatic heart disease (RHD) remains a major public health concern in low‑ and middle‑income countries. Systematic comparisons between China and the ten ASEAN member states examining sex disparities are scarce. Methods: Using Global Burden of Disease Study 2023 data, we analyzed RHD burden in China and ten ASEAN countries from 1990 to 2023. Key measures included age‑standardized prevalence (ASPR), mortality (ASMR), and disability‑adjusted life‑years rates (ASDR). Temporal trends were assessed via estimated annual percentage changes (EAPCs) and joinpoint regression. Decomposition analysis quantified contributions of population aging, growth, and epidemiological change. Age‑period‑cohort modeling and ARIMA forecasting (2024‑2030) were applied. Results: From 1990 to 2023, China achieved steeper declines in ASDR (EAPC: -7.03 vs -2.40) and ASMR (-7.07 vs -2.87) than ASEAN. In 2023, Cambodia, Myanmar, and Laos had the highest burdens; Singapore, Brunei, and Thailand were comparable to China. Females consistently had higher rates than males across all indicators, with wider sex disparity in ASEAN (female‑to‑male ASDR ratio 1.6 vs 1.1 in China). Decomposition analysis showed that China's female DALY decline was driven by epidemiological improvement (189.7%), whereas in ASEAN population growth largely offset gains (-145.9%). Joinpoint analysis revealed that China's female ASDR and ASMR plateaued after 2020, while ASEAN's female ASPR increased in 2021-2023 (APC: 0.22). Projections suggested that by 2030 China's female ASMR would fall below the ASEAN average, potentially positioning China as a regional low‑burden benchmark for all three female indicators. Conclusion: China has made remarkable progress in reducing female RHD burden, outpacing ASEAN. However, the observed post‑2020 plateau in China and the recent rise in female prevalence in ASEAN demand renewed efforts. Persistent sex disparities underscore the urgent need for targeted secondary prophylaxis and regional cooperation, particularly for women of childbearing age in high‑burden countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.